Levation Pharma
Topical Oxymetazoline for Cosmetic Eye Lifts
Company Overview
Snapshot
Founded in September 2017 by Houman David Hemmati MD, PhD, Levation Pharma operates with 1–10 employees. The company has secured $1.93 million across one funding round from two investors. In February 2023, Levation Pharma received FDA clearance to initiate a Phase I/II clinical trial for LEV102, its treatment for Acquired Blepharoptosis.
Business overview
Levation Pharma is an Israeli-American company focused on developing treatments for Acquired Blepharoptosis, a condition characterized by drooping upper eyelids. The company's core product, LEV-102, is a proprietary odorless, colorless, rapidly drying aqueous gel containing oxymetazoline. Designed for topical application to the upper eyelids, LEV-102 aims to stimulate Mueller’s muscle to lift the eyelid. The company operates within the Health Tech & Life Sciences sector, specifically targeting pharmaceuticals and cosmetics markets with its drug discovery and development efforts.
Strategic signal
In February 2023, Levation Pharma received FDA clearance to initiate a Phase I/II clinical trial for LEV102, its treatment for Acquired Blepharoptosis. This clearance is a critical regulatory and developmental milestone, signaling to investors the company's progress in advancing its lead therapeutic candidate towards commercialization and validating its scientific approach in ophthalmology and aesthetic therapeutics.
Log in to access full profile ›Company Intelligence Q&A
- What is Levation Pharma's primary focus?
- Levation Pharma specializes in the treatment of Acquired Blepharoptosis, a condition involving drooping upper eyelids, through its proprietary topical solutions.
- What is LEV-102?
- LEV-102 is Levation Pharma's proprietary odorless, colorless, rapidly drying aqueous gel. It contains oxymetazoline as the active pharmaceutical ingredient, designed to penetrate the upper eyelid and stimulate Mueller’s muscle to lift the lid.
- When did Levation Pharma initiate its Phase I/II clinical trial for LEV102?
- In February 2023, Levation Pharma initiated a Phase I/II clinical trial for LEV102 following FDA clearance. This trial aims to assess the preliminary safety and efficacy of the treatment for Acquired Blepharoptosis.
- Who are the founders of Levation Pharma?
- Levation Pharma was founded by Houman David Hemmati MD, PhD.
- Which investors participated in Levation Pharma's funding round?
- Levation Pharma received funding from investors including Peregrine Ventures and Pontifax.